Therefore, enhanced STAT3 signaling could contribute to high Bcl-2 expression in treated patients, as we observed significantly higher levels of basal STAT3 phosphorylation in CD4+ T-cells from patients on therapy compared to untreated patients with CLL. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.